At the time of writing, AIM ImmunoTech Inc [AIM] stock is trading at $0.12, down -0.79%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The AIM shares have gain 1.30% over the last week, with a monthly amount drifted -15.08%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
For the past year, the stock price of AIM ImmunoTech Inc fluctuated between $0.11 and $0.62. AIM ImmunoTech Inc [AMEX: AIM] shares were valued at $0.12 at the most recent close of the market.
Analyzing the AIM fundamentals
According to AIM ImmunoTech Inc [AMEX:AIM], the company’s sales were 0.19M for trailing twelve months, which represents an -23.91% plunge. Gross Profit Margin for this corporation currently stands at 0.2% with Operating Profit Margin at -146.88%, Pretax Profit Margin comes in at -125.94%, and Net Profit Margin reading is -125.94%. To continue investigating profitability, this company’s Return on Assets is posted at -1.76, Equity is -3.98 and Total Capital is -8.0. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.17.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.1157 points at the first support level, and at 0.1063 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.1347, and for the 2nd resistance point, it is at 0.1443.
Ratios To Look Out For
It is important to note that AIM ImmunoTech Inc [AMEX:AIM] has a current ratio of 0.75. Also, the Quick Ratio is 0.75, while the Cash Ratio stands at 0.09. Considering the valuation of this stock, the price to sales ratio is 45.21, the price to book ratio is 2.52.
Transactions by insiders
Recent insider trading involved Equels Thomas K, CEO & President, that happened on Mar 05 ’25 when 50000.0 shares were purchased. CEO & President, Equels Thomas K completed a deal on Mar 04 ’25 to buy 44000.0 shares. Meanwhile, CEO & President Equels Thomas K bought 83334.0 shares on Mar 04 ’25.
